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tively, and remained stable till 12 years. The hypoesthesia ac-
tuarial rate at 6 months, 1 and 2 years was 11.5, 11.5 and 16%, 
and remained stable till 12 years.  Conclusions: GKS proved 
safe and effective in this special group of patients. 
 © 2014 S. Karger AG, Basel 
 Introduction 
 Trigeminal neuralgia (TN), also known as ‘tic doulou-
reux’, is a serious health problem, with a prevalence rate 
of 4–5 per 100,000 people  [1] . The association of TN and 
multiple sclerosis (MS) has been known since the end of 
the 19th century  [2] . The pathophysiology is considered 
related to a demyelination phenomenon involving the tri-
geminal nerve. Trigeminal pain has usually the same fea-
tures and the same chronic and paroxysmal pain charac-
teristics as classical TN (CTN), except for the fact that it 
is more frequently bilateral. Burchiel and Slavin  [3]  clas-
sified the MS-related TN as symptomatic. TN secondary 
to MS is additionally more often difficult to manage phar-
macologically and surgically, with lower response rates 
than CTN  [4–6] .
 Key Words 
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 Abstract 
 Background: Trigeminal neuralgia (TN) related to multiple 
sclerosis (MS) is more difficult to manage pharmacologically 
and surgically.  Objective: This article aims to evaluate the 
safety and efficacy of Gamma Knife surgery (GKS) in this spe-
cial group of patients.  Methods: Between July 1992 and No-
vember 2010, 43 cases with more than 1 year of follow-up 
were operated with GKS for TN related to MS and prospec-
tively evaluated in the Timone University Hospital, Marseille, 
France. Radiosurgery using the Gamma Knife (model B or C or 
Perfexion) was performed. A single 4-mm isocenter was posi-
tioned at a median distance of 8 mm (range 5.7–14.7) anterior 
to the emergence of the nerve. A median maximum dose of 
85 Gy (range 75–90) was delivered.  Results: The median fol-
low-up period was 53.8 months (12–157.1). Thirty-nine pa-
tients (90.7%) were initially pain free. Their actuarial probabil-
ity of remaining pain free without medication at 6 months, 1, 
3, 5 and 10 years was 87.2, 71.8, 43.1, 38.3 and 20.5%, respec-
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 The number of articles reporting the safety and effi-
cacy of Gamma Knife surgery (GKS) in TN has continu-
ally increased since 1996  [7] ; however, only 5 dedicated 
studies about the role of GKS in MS-related TN are avail-
able up-to-date  [8–12] . Furthermore, the number of pa-
tients and their follow-up in published series are limited.
 We report a single-institution experience in the Tim-
one University Hospital, Marseille, France. We prospec-
tively assessed the initial pain cessation, hypoesthesia and 
recurrence actuarial rates. The present series has the big-
gest number of cases in the current literature, with a very 
long-term follow-up.
 Methods 
 Patient Population and Selection 
 Between July 1992 and November 2010, 737 patients present-
ing with intractable TN were treated with GKS and followed up 
prospectively in the Timone University Hospital in Marseille, 
France. Patients fulfilling the criteria of the International Head-
ache Society (2003)  [13] were accepted for treatment.
 Evaluation of the type of trigeminal pain was made according 
to the classification proposed by Eller et al.  [14] into idiopathic 
TN1 and TN2. While TN1 is described as typically sharp, shooting, 
electrical shock-like, with pain free intervals between the attacks, 
TN2 is described as an aching, throbbing or burning pain, for more 
than 50% of the time and constant in nature (constant background 
pain being the most significant attribute). Of these patients, 57 
(7.7%) had a MS-related TN. We further selected for analysis 43 
cases with more than 1 year of follow-up.
 Radiosurgical Technique 
 During the 18 years of the study, various models of the Gam-
ma Knife were used (models B, C, 4C or Perfexion, Elekta Instru-
ments Inc.). After application of the Leksell Model G stereotactic 
frame (Elekta Instruments) under local anesthesia, all patients 
underwent stereotactic magnetic resonance imaging (MRI) and 
computer tomography (CT scan) to identify the trigeminal nerve. 
The MRI sequences used are T2-weighted type CISS (Siemens) 
without contrast and contrast-enhanced T1-weighted images. 
CT scans routinely supplement the neuroradiological investiga-
tion in order to correct any distortion errors on the MRI images 
 [15] .
 In the Gamma Unit in Marseille, France, we use the anterior 
target, which means placing a unique isocenter on the cisternal 
portion of the trigeminal nerve using a very anterior target, located 
immediately posterior to the gasserian ganglion, as described pre-
viously  [15, 16], at a median distance (if possible) of approximate-
ly 7.5 mm from the entry of the trigeminal nerve into the brain-
stem, if the anatomical conditions allow this. We initially give a 
dose of 90 Gy at the 100% isodose. Beam channel blocking is used 
depending on the dose received by the first 10 mm 3 of the brain-
stem: should this dose be more than 15 Gy, we diminish the dose 
and start plugging so as to be able to avoid increasing the length of 
the treated nerve which could account for more toxicity (the so-
called ‘Flickinger effect’)  [15] .
 A single 4-mm isocenter was used for all 43 patients (100%) and 
was positioned in the cisternal portion of the trigeminal nerve at a 
median distance of 8 mm (range 5.7–14.7) anterior to the entrance 
of the trigeminal nerve into the brainstem.
 A median maximum dose of 85 Gy (range 75–90) was deliv-
ered. Further analysis of the maximum doses revealed 40 available 
data with 2 patients (4.6%) receiving 75 Gy, 7 patients (16.3%) re-
ceiving 80 Gy, 17 patients (39.5%) receiving 85 Gy and 14 patients 
(32.5%) receiving 90 Gy, respectively. So, overall, 88.3% of the pa-
tients received a maximum dose of at least 80 Gy in this series.
 Patients continued their medication unchanged for 1 month 
after GKS and then were able to reduce the drug doses depending 
on the treatment efficacy. We usually evaluated these patients for 
a neurological examination including facial sensibility and motil-
ity and corneal reflex at 3 months, 6 months and 1 year after the 
treatment and then regularly once a year.
 A team consisting of a neurosurgeon, radiation oncologist and 
a medical physicist performed dose selection and planning.
 Follow-Up and Assessment of Outcome 
 The Université de la Méditerranée and the Direction and the 
Ethical Committee of the Timone University Hospital (CPPRB 1) 
approved our study. Follow-up information was obtained in two 
ways: direct clinical evaluation or telephone interview by the first 
author (C.T.) who was not involved in the selection of the cases for 
treatment.
 We evaluated the initial pain cessation, the onset of the sensory 
disturbance and the recurrence. We analyzed the data regarding 
the latency intervals to achieve the features, making sure to date 
every event, the use of medication and the need for surgical proce-
dures, so as to accurately assess all the information available.
 Pain was scored using 3 different scales: Barrow Neurological 
Institute scale (BNI; class I: no trigeminal pain, no medication; 
II: occasional pain, not requiring medication; IIIa: no pain, con-
tinued medication; IIIb: controlled with medication; IV: some 
pain, not adequately controlled with medication; V: severe pain, 
no pain relief), Burchiel (class I: pain free, no medication; II, pain 
free on medication; IIIa: pain improved, no medication; IIIb: 
pain improved, on medication; IV: pain not improved) and Regis 
(class I: no trigeminal pain, no medication; II: no pain, with med-
ication; III: pain frequency reduction >90%; IV: pain frequency 
reduction 50–90%; V: no pain reduction; VI: pain worsening) 
 [14, 16, 17] .
 For hypoesthesia evaluation, we used the BNI facial hypoesthe-
sia scale (class I: no facial numbness; II: mild facial numbness, not 
bothersome; III: facial numbness, somewhat bothersome; IV: fa-
cial numbness, very bothersome)  [17] . For patients presenting fa-
cial sensory dysfunction, we also inquired about their quality of life 
related to TN and whether this sensory problem was bothering 
them or not. We furthermore asked whether or not they had mas-
tication difficulties.
 The patients and referring doctors were instructed to continue 
the medication unchanged for at least 1 month and then it was sug-
gested to reduce the drug doses progressively if they were pain free. 
A case report form was created and filled in prospectively as from 
the first patient. The initial follow-up was based on clinical evalu-
ation, all patients being seen in person for proper evaluation of 
safety and efficacy, with a neurological examination including fa-
cial sensibility and motility and corneal reflex at 3 months, 6 
months and 1 year after the treatment and then regularly once a 
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year. Every clinical evaluation made by our medical team during 
the follow-up course was prospectively noted in the database so as 
to have continuous up-to-date information.
 Statistical Analysis 
 Data were recorded using Microsoft Excel 2000. All statistical 
analysis was performed using the R software, version 2.12.0 (R 
Foundation for Statistical Computing, Vienna, Austria). The sur-
vival R package was used for survival analysis.
 First, a descriptive analysis of recorded data was realized among 
the MS-related TN population.
 For the evaluation of outcomes such as initial pain cessation, 
hypoesthesia and recurrence, time to event was estimated by using 
the Kaplan-Meier method. A bivariate analysis was then per-
formed to identify predictive factors among the collected variables. 
For qualitative variables, Kaplan-Meier curves were used to graph-
ically represent survival among the different groups, and they were 
compared using the univariate log-rank test. For all variables, the 
effects were estimated and tested by fitting univariate Cox propor-
tional hazards regression models. Proportionality of hazards was 
assessed graphically by log cumulative hazard plots.
 To determine the outcome efficacy, its rate was estimated.
 For qualitative variables, the χ 2 test was performed when valid; 
otherwise the exact Fischer test was used. All tests were 2-sided, 
and p values of less than 0.05 were judged to be significant.
 Results 
 General Data 
 In this series, 23 (53.5%) of all patients were men and 
20 (46.5%) were women. The median age was 57.2 years 
(range 36.1–82.6). The median duration of symptoms 
was 72 months (range 2–390). The median follow-up pe-
riod was 53.8 months (range 12–157.1).  Table 1 shows a 
preoperative assessment of our population in terms of 
clinical evaluation.
 Pain was slightly predominant on the left side in 22 
patients (51.2%) compared to on the right side in 21 pa-
tients (48.8%). Only 2 patients (4.6%) had bilateral pain. 
Pain was predominantly distributed in the V2 and V3 
dermatome of the trigeminal nerve (37.2%), followed by 
V3 (30.2%), V2 (16.3%), V1 and V2 and V3 (6.9%), V1 
(4.6%), V1 and V2 (4.6%), and V1 and V3 (2.3%).
 Two patients (4.6%) died but were not excluded from 
the study as they had had at least 1 year of follow-up at 
the time of their death.
 Preoperative MRI revealed the presence of a vascular 
conflict in 15 cases (34.9%).
 Surgery had previously failed in 21 patients (48.8%), 7 
(16.3%) of whom had only had 1 previous intervention, 8 
(18.6%) had had 2 previous surgeries and 6 (13.9%) had 
had 3 or more previous surgeries. The preoperative tech-
nique used was radiofrequency lesion in 11 (25.6%) pa-
tients, balloon microcompression in 10 (23.2%), micro-
vascular decompression in 3 (7%) and glycerol rhizotomy 
in 1 (2.3%) patients, respectively ( table 2 ).
 Seventeen patients (39.5%) had preoperative sensory 
disturbances, which was severe in 2 cases (4.7%).
 Medical and surgical treatment had failed in the ma-
jority of our patients.
 Gamma Knife surgery was the first surgical procedure 
in 22 patients (51.2%).
 Initial Pain Cessation 
 Thirty-nine patients (90.7%) had initial pain cessation 
in a median time of 30 days (range 0–90). The initially 
pain free actuarial rate at 15 days, 1, 2 and 3 months was 
44.2, 58.1, 81.4 and 90.7%, respectively, and remained sta-
ble till 12 months ( fig. 1 ).
 The age at the time of GKS (p = 0.09), the side of the 
pain (p = 0.37), bilaterality of the pain (p = 0.16), the 
number of dermatomes in which the pain presented (p = 
0.367), the time elapsed till treatment onset (p = 0.32), the 
topography of the pain (p = 0.91 for V1, 0.62 for V2 and 
0.53 for V3), previous surgery (p = 0.4) and previous side 
effects (p = 0.49) were not statistically significant.
 The preoperative neurovascular conflict was statisti-
cally significant with a positive predictive value, with a p 
value of 0.03 (hazard ratio of 0.47 and confidence interval 
between 0.24 and 0.94).
 Table 1.  Preoperative general assessment
Variable Patients, n (%)
Gender
Male
Female
23 (53.5)
20 (46.5)
Side of pain
Right
Left
21 (48.8)
22 (51.2)
Pain distribution
V2
V2 and V3
V3
V1 and V2
V1 – 3
V1
V1 and V3
7 (16.3)
16 (37.2)
13 (30.2)
2 (4.6)
3 (6.9)
2 (4.6)
1 (2.3)
Typical pain 36 (83.7)
Atypical pain 7 (16.3)
Dead 2 (4.6)
Preoperative MRI vascular conflict other
than megadolichobasilar compression 15 (34.9)
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 Sensory Dysfunction after GKS 
 Four patients (16%) without preoperative hypoesthe-
sia developed facial numbness after GKS ( fig. 2 ). The hy-
poesthesia actuarial rate at 0.5, 1 and 2 years was 11.5, 
11.5 and 16%, respectively, and it remained stable till 12 
years with a median delay of onset of 6 months (range 
2–22). No patient reported a bothersome hypoesthesia. 
They all considered that their quality of life improved af-
ter GKS and that the sensory dysfunction was a good 
trade-off for pain relief. No case of anesthesia dolorosa 
was found after GKS.
 The gender (p = 0.31), age (p = 0.26), time elapsed till 
treatment onset (p = 0.16), previous surgery (p = 0.317), 
preoperative neurovascular conflict (p = 0.13) and the 
numbers of territories involved in the pain (p = 0.65) were 
not statistically significant.
 The topography of pain within the V1 dermatome was 
associated with a higher risk of numbness, with a p value 
of 0.08 (hazard ratio 5.6).
 No patients developed a trigeminal motor deficit or 
any other cranial nerve deficit after GKS.
 Recurrent Pain and Salvage Therapy 
 Twenty-four patients (61.5%) experienced at least 1 re-
currence after the GKS treatment. The median time to 
recurrent pain was of 16 months (range 1.6–146.7).
 Because of recurrent medically refractory pain, 22 
(51.2%) patients required further surgeries (for postop-
erative assessment, see  table 3 ). Ten patients (23.2%) re-
quired 1 surgical procedure compared to 8 (18.6%) with 
2 procedures and 4 (9.3%) requiring at least 3 surgeries. 
In our unit the most common intervention after failed 
GKS was balloon microcompression, performed in 16 
 Table 2.  Preoperative surgical assessment 
Variable Patients
with TN, n (%)
No prior surgery 22 (51.2)
Prior surgery
1
2
≥3
21 (48.8)
7 (16.3)
8 (18.6)
6 (13.9)
Type of prior surgery
Radiofrequency lesion
Balloon microcompression
Microvascular decompression
Glycerol rhizotomy
11 (25.6)
10 (23.2)
3 (7)
1 (2.3)
Side effects from prior surgery 17 (39.5)
Facial sensibility before GKS
Normal
Slight hypoesthesia
Severe hypoesthesia
Anesthesia
26 (60.5)
15 (34.9)
2 (4.7)
0
0 2 4 6
Years after radiosurgery
8 10 12
0
0.2
0.4
0.6
0.8
1.0
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 Fig. 1. Kaplan-Meier estimate of the probability of initial pain free-
dom after GKS. 
 Fig. 2. Kaplan-Meier estimate of the probability of hypoesthesia 
onset after GKS. 
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(37.2%) patients, followed by radiofrequency lesion in 5 
(11.6%) cases, and a second GKS and cortical stimulation 
in 2 cases each (4.7%).
 The actuarial probability of maintaining pain relief 
without medication at 6 months, 1, 2, 3, 5, 7 and 10 years, 
respectively, was 87.2, 71.8, 53.6, 43.1, 38.3, 27.4 and 
20.5% and remained stable till 12 years ( fig. 3 ).
 Age (p = 0.64), the number of dermatomes involved in 
the trigeminal pain (p = 0.97), the side (p = 0.11), gender 
(p = 0.68), bilaterality (p = 0.42), atypical pain (p = 0.21), 
previous surgery (p = 0.73), postoperative GKS hypoes-
thesia (p = 0.43) as well as the time elapsed till treatment 
onset were not statistically significant.
 Results at Last Follow-Up 
 The results of the last follow-up showed a good out-
come in 41 patients (95.3%) in the BNI classification, in 
36 (83.7%) in the Burchiel classification and in 41 (95.3%) 
in the Regis classification ( table 4 ).
 Discussion 
 The incidence of MS-related TN varies from one study 
to another as follows: 1–2%  [18] , 2.4% in a large series of 
800 patients  [19] , 4.4%  [2] , 5.1%  [12] , and 6.3%  [10] . In 
our population, the incidence rate was 7.73% (57 pa-
tients), which is within the range presented in the current 
literature.
 TN is usually caused by demyelination of trigeminal 
sensory fibers within either the nerve root or, less com-
monly, within the brainstem  [18, 20] . In the case of MS, a 
plaque of demyelination encompasses the root entry zone 
of the trigeminal nerve in the pons  [21] . Additionally, sev-
eral studies have also described the association of a neu-
rovascular conflict in a minority of patients  [4, 22–24] . 
Love and Coakham  [20] demonstrated that demyelin-
ation is found to extend along the proximal part of the 
trigeminal nerve root and, in some cases, right up to its 
junction with the peripheral nervous system. Some other 
findings were also reported: the astrocyte processes are 
usually more numerous and widely distributed within the 
regions of demyelination; lipid-laden macrophages are 
present as well as juxtaposed axons and variable numbers 
 Table 3.  Postoperative global assessment
Variable Patients with
essential TN, n (%)
Initially pain free 39 (90.7)
Post-GKS sensory dysfunction
Mild
Severe
4 (16)
4 (100)
0 
BNI facial hypoesthesia (GKS-related) scale
No facial numbness 22 (84)
Mild facial numbness 4 (16)
Facial numbness, somewhat bothersome 0 
Facial numbness, very bothersome 0 
Recurrence of pain 24 (61.5)
Additional treatment after GKS
1
2
≥3
Balloon microcompression
Radiofrequency lesion
Second GKS
Cortical stimulation
Microvascular decompression
Glycerol
22 (51.2)
10 (23.3)
8 (18.6)
4 (9.3)
16 (37.2)
5 (11.6)
2 (4.7)
2 (4.7)
0 
0 
0 2 4 6
Years after being pain free
8 10 12
0
0.2
0.4
0.6
0.8
1.0
Pr
ob
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ili
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 Fig. 3. Kaplan-Meier estimate of the probability of maintaining 
pain relief. 
 Table 4.  Results at the last follow-up
BNI
classification
Burchiel 
classification
Regis
classification
Good result 41 (95.34%) 36 (83.72%) 41 (95.34%)
Poor result 2 (4.65%) 7 (16.27%) 2 (4.65%)
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of thinly myelinated fibers, both within and immediately 
adjacent to the regions of demyelination.
 Several articles discussed the role of GKS in the arma-
mentarium of treatment for MS-related TN, either taking 
this case separately ( table 5 ) or discussing it in the global 
context of CTN.
 Huang et al.  [9] analyzed 7 patients with TN related to 
MS from a larger group of 50 patients. Their median fol-
low-up in this series was 28 months. All 7 patients showed 
excellent responses to GKS. The rate of complication was 
relatively high, with hypoesthesia found in 4 patients 
(57.1%). The recurrence rate was low, with only 1 case 
(14.3%). Interestingly, they report that the patient who 
had a recurrence also required the longest time to initial 
response (5 months) and the longest time to complete 
resolution of pain (8 months).
 Rogers et al.  [10] reported a series of 15 patients with 
a mean follow-up of 17 months. Twelve patients (80%) 
experienced pain relief after the procedure. Two patients 
(13%) developed facial numbness and also experienced 
complete pain relief. Five patients (33.3%) experienced a 
recurrence and were retreated with the same procedure 
and target, but with a lower maximal dose. They all im-
proved further.
 Zorro et al.  [12] evaluated the outcomes for 37 patients 
with a median follow-up of 56.7 months (range 6–174). 
Complete pain relief was found in 23 patients (62.1%) im-
mediately after the GKS and in 36 (97.3%) at some point 
in their course of treatment, respectively. The complica-
tion rate was 5.4%. The probability of maintaining pain 
relief after GKS was 82.6% at 1 year, 73.9% at 3 years and 
54% at 5 years. In this paper, an important number of pa-
tients with MS-related TN (11 patients, 29.7%) had bilat-
eral pain. As underlined before, this fact had also been 
stated by other studies  [25, 26] .
 Recently, Jeremy Rowe (in Loescher et al.  [27] ) pub-
lished a paper containing an analysis of 72 patients treat-
ed for TN (58 cases of CTN and 14 cases of secondary TN) 
in the National Center for Stereotactic Radiosurgery in 
Sheffield. They furthermore analyzed 8 patients with TN 
secondary to MS. Interestingly, 2 of these 8 patients had 
been treated bilaterally (on separate occasions). Of these 
8 patients, 3 (37.5%) were pain free and 6 (75%) were very 
satisfied. In secondary trigeminal neuralgia (MS includ-
ed), the hypoesthesia rate was 29%. The rate of recurrence 
was not further discussed in this subgroup but was re-
ported in the global series.
 Weller et al.  [11] analyzed a series of 35 cases with a 
median follow-up of 39 months (range 3–97). If initially 
the target was the root entry zone, further on in the course 
of treatments the retrogasserian target was used  [15, 16] , 
as reported by our group. The overall initial response 
(BNI I–III) was 82% in a median time of 42 days (range 
2–170). The rate of numbness was rather high (39%); the 
authors considered this to be related to the use of higher 
doses and a root entry zone target early in their series.
 Table 5.  Main series of the literature with regard to the role of GKS in the treatment of TN secondary to MS
Authors Patients,
n
Median/
mean age,
years
 Dose maximum, % DE, mm Median FU,
months
Patients, %
<70 
Gy
70 – 80 
Gy
>80 
Gy
without
pain
>90% side effects recur-
rence
Tuleasca et al., 2014 
(current study)
43 57.2 
(36.5 – 82.6)
0 28 72 median 8
(5.7 – 14.7)
53.8 
(12 – 157.1)
90.7 90.7 16 61.5
Weller et al. [11], 
2013
35 62 
(39 – 86)
median 90
(80 – 90)
near REZ
retrogasserian
39 
(3 – 97)
35 88 39 –
Diwanji et al. [8], 
2010
13 – median 75
(70 – 80)
REZ 67 
(13 – 96)
42 57 7 –
Zorro et al. [12], 
2009
37 59 
(38 – 74)
median
80
2 – 8 56.7 
(6 – 174)
62.1 97.3 5.4 37.8
Rogers et al. [10], 
2002
15 – 12 3 REZ mean of 17 
(6 – 38)
– 80 13 33.3
Huang et al. [9], 
2002
7 51 
(40 – 63)
5 2 REZ 28 
(13 – 38)
– 100 57.1 14.3
Figures in parentheses indicate minimum and maximum values. DE = distance from the emergence; FU = follow-up; REZ = root entry zone.
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 Some other authors focused on the same topic, but 
without specific and detailed information: Urgošik et al. 
 [28] stated a poor response rate to GKS, with 4 out of 7 
patients having 40–100% residual pain. Only 3 patients 
experienced complete pain relief and a further recurrence 
4–9 months later. Verheul et al.  [29] reported 46% pain 
relief at 5 years in the MS group.
 In a recent paper Cruccu et al.  [30] referred to the role 
of surgery versus pharmacotherapy in the management 
of trigeminal neuralgia in patients with MS, stating that it 
remains uncertain. Even if in general we can agree with 
this approach, when dealing with a patient presenting 
with acute pain, drugs may be sometimes insufficient. If 
surgery is decided upon, it should follow after an analysis 
of several factors, especially the medical history of the pa-
tient. Even if the probability of recurrence is higher than 
in the CTN cases, as our data also suggest, we must dif-
ferentiate between an acute crisis of TN, a MS disease 
peak or a chronic TN. The authors found no evidence of 
criteria based on which surgeries should be chosen and 
performed. Most authors recommend gasserian ganglion 
procedures unless a vascular compression is identified. 
Even in this former case some authors suggested less ef-
ficacy and increased side effects for MS-related TN cases, 
e.g. Broggi et al.  [31] and Eldridge et al.  [32] for microvas-
cular decompression, Kanpolat et al.  [5] for radiofre-
quency lesioning and Kondziolka et al.  [6] for glycerol 
rhizotomy. This is probably related to a different physio-
pathological context, disease related.
 Conclusions 
 The current series of 43 cases with more than 1 year of 
follow-up is the largest in the literature, with a very long-
term follow-up. In our experience, GKS proved to be safe 
and effective for treating TN due to MS. The initial rate 
of pain cessation was high (90.7%), with a low rate of 
numbness of 16%, never bothersome or disabling; addi-
tionally, no anesthesia dolorosa was found. The rate of 
recurrence was high (61.5%), related to this specific clin-
ical entity.
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